spacer
home > ebr > summer 2018 > visualising alzheimers
PUBLICATIONS
European Biopharmaceutical Review

Visualising Alzheimers

Dementia, a condition describing an array of symptoms including memory loss and cognitive degeneration, affects 47 million people worldwide (1). Alzheimer’s disease (AD), the most common cause of dementia, leads to protein build-up in the brain in the form of plaques. These plaques interfere with nerve cell connections, ultimately causing nerve cell death and brain tissue loss. For some time, the amyloid hypothesis has been described as the leading cause of AD: amyloid-β (Aβ), an insoluble peptide, has been characterised in the plaques found in the brains of patients with AD. Formation of Aβ arises from the cleavage of a much larger protein called amyloid precursor protein. Before becoming plaques, Aβ monomers (individual peptides) clump together into oligomers, which can be seen in early onset AD. These oligomers progress to form the neurotoxic plaques. Although the amyloid hypothesis has been well-understood for a number of years, the characterisation of Aβ structural assembly requires more in-depth research to improve comprehension of AD pathogenesis and better develop appropriate diagnostic and therapeutic biomarkers. Mass spectrometry-based proteomic analysis is a valuable approach that characterises the variety of Aβ species in brain tissues. Matrix-assisted laser desorption/ionisation (MALDI) imaging mass spectrometry has shown advantages compared with traditional immunohistochemistry (IHC) methods to determine the localisation of Aβs in brain tissue.

MALDI in Practice

The Department of Medical Life Systems at Doshisha University houses a leading laboratory using MALDI imaging mass spectrometry (MALDI-IMS) to advance its research across the genomics and proteomics field. The lab is pioneered by Professor Masaya Ikegawa, whose current prime focus is the deposition of Aβ in the brains of patients with AD (2). The lab aimed to characterise the distribution of individual Aβ peptides in the autopsied brains of elderly subjects, and those suffering from AD and cerebral amyloid angiopathy (CAA) (see Figure 1).

In typical Alzheimer’s neuropathy, IHC methods have been used in the past to determine the localisation of Aβ peptides in brain tissues. However, this technique cannot discriminate between different variants when a number of epitopes are used simultaneously, risking the introduction of bias. Mass spectrometry-based proteomic analysis has gained popularity as an alternative method for characterising the variety of Aβ species in the brain, and, most recently, MALDI-IMS has emerged as an important tool for investigating protein and small molecule distribution within biological systems. MALDI imaging can individually track the whole distribution of complex molecules having multiple modifications, which is an advantage over IHC. Previously, the signal could be vague, but, even with a muddy biological matrix at 100μm resolution, the MALDI imaging mass spectrometer provides high-quality results.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Shannon Cornett received his PhD in analytical chemistry from the University of Georgia, US. Following a postdoctoral with at City of Hope National Medical Centre, US he joined Bruker and worked in the roles of Applications Scientist, TOF R&D Manager, and TOF Product Manager. In 2002, Shannon moved to the Mass Spectrometry Research Facility at Vanderbilt University as Research Assistant Professor, developing new tools and methodologies for the thenemerging field of imaging mass spectrometry. He rejoined Bruker Daltonics in 2009 to support the MALDI imaging product lines and now manages the imaging business.
spacer
Dr Shannon Cornett
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Zenith Technologies win Cork Company of the Year

We’re very proud to announce that last Friday we won the Cork Company of the Year Award in the corporate category.
More info >>

White Papers

Bio/Pharmaceutical Methods: Do your Analytical Methods Hold Up to Regulatory Scrutiny?

Eurofins BioPharma Product Testing

As FDA guidelines evolve and drug products on the market begin to age, bio/pharmaceutical manufacturers face scrutiny of the original methods used to support these products. Therefore, manufacturers must re-evaluate these methods to ensure they comply with current FDA expectations. Some manufacturers are even facing consent decrees imposed by the agency requiring them to bring methods up to current standards within a specified timeframe. This exercise requires significant amounts of time and resources, which many manufacturers do not have since they are focused on getting their next products to market. For that reason, some clients have been turning to Eurofins Lancaster Laboratories for support.
More info >>

 
Industry Events

Highly Potent Active Pharmaceutical Ingredients (HPAPI)

13-14 May 2019, Copthorne Tara Hotel, London, UK

SMi is delighted to announce its 3rd Annual Highly Potent Active Pharmaceutical Ingredients conference coming to London on the 13th-14th May 2019. The HPAPI global market has developed rapidly in the past year and is continuing to expand into the future, with over a quarter of drugs in development worldwide being classified as highly potent. As a result, there is a growing demand for both pharmaceutical and contracted manufacturers to adapt to the evolving HPAPI landscape.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement